

10/275047

IAP20 Res'd PCT/PTO 04 APR 2006

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Merck & Co., Inc.
Int'l Appln. No. : PCT/US2004/035112
Int'l Date Filed : 20 October 2004 (10/20/2004)
Serial No. : (To be assigned) Case No.: 21179Y
Filed : April 4, 2006
For : ENHANCEMENT OF GROWTH HORMONE LEVELS
WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR
AND A GROWTH HORMONE SECRETAGOGUE

Commissioner for Patents
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT April 4, 2006
EXPRESS MAIL NO. EV660608090 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Lori Schepisi
DATE April 4, 2006

Serial No.:

To be assigned

Case No.:

21179Y

Page:

2

APR 20 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



J. Eric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: April 4, 2006

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	(To be assigned) 38/575047	
			Filing Date		
			First Named Inventor	Hogenhuis	
			Group Art Unit		
			Examiner Name		
Sheet	1	of	1	Attorney Docket Number	21179Y

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US 5,939,560		JENKINS et al	08/17/1999
		US 5,536,716		Chen, et al.	07/16/1996
		US 6,699,871		Edmondson, et al.	03/02/2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--